Cancer Pathogenesis and Therapy
Publisher: Elsevier · ISSN 2949-7132 · 37 articles
- Kirsten rat sarcoma viral oncogene (KRAS) G12D and pan-RAS inhibitors in pancreatic ductal adenocarcinoma: clinical progress and strategies to overcome resistance
- Genetically predicted inflammatory mediators link mitochondrial function to breast cancer risk: A Mendelian randomization study
- Longitudinal assessment of biopsy-resection histological discordance in digestive tract epithelial neoplasms and development of a colorectal upgrading prediction model
- Low-incidence adverse events (AEs): An emerging challenge in chimeric antigen receptor T-cell (CAR-T) therapy
- MicroRNA (miRNA) dysregulation in virus-associated cancers: From molecular mechanisms to therapeutic breakthroughs
- Mechanistic target of rapamycin complex (mTORC)-glutamine axis in cancer: Mechanistic crosstalk, therapeutic resistance, and clinical opportunities
- Cover
- Table of Contents
- Moving cardio-oncology upstream: Integrating cardiovascular prevention into routine cancer care
- Rewiring metabolic-immune circuitry in pancreatic ductal adenocarcinoma (PDAC)
- Advances in radiotherapy-based multimodal treatment for non-small-cell lung cancer
- Beyond chemotherapy: The rise of nucleic acid nanoformulations in personalized lung cancer therapy
- Cancer therapy-induced cardiotoxicity: mechanisms, biomarkers, psychological stress, and emerging therapeutic strategies
- From fusion partner to clinical practice: A treatment-oriented framework for transcription factor E3 (TFE3)-rearranged renal cell carcinoma
- Mortality risk in patients with urological malignancies and human immunodeficiency virus (HIV) coinfection: A systematic review and meta-analysis of cohort studies
- Efficacy and safety of SCT200 in patients with recurrent or metastatic head and neck squamous cell carcinoma after platinum failure: A phase 2 trial
- Integrin α3 (ITGA3) expression across breast cancer subtypes: Prognosis and therapeutic relevance
- An immune exhaustion signature predicts prognosis and identifies patients with diffuse large B-cell lymphoma (DLBCL) who derive preferential benefit from chimeric antigen receptor (CAR)-T cell therapy
- Call for Papers | Special Issue
- A classification-first pathway for reproductive and endocrine health after radiotherapy for skull-base-adjacent malignancies
- DKK1-CKAP4 axis functions as an immunometabolic checkpoint linking tumor-intrinsic signaling with immune suppression
- Divergent Melanoma Trajectories in the Western Pacific: Declining Mortality in Oceania and Diagnostic Challenges for Non-UV Subtypes in Asia
- Cardiotoxicity of Novel Hemato-Oncology Therapies: Mechanisms, Monitoring, and Multidisciplinary Management
- Tn-Associated Truncated O-linked N-acetylgalactosamine (O-GalNAc) Glycosylation in Pancreatic Cancer: Mechanisms, Biomarkers, and Therapeutic Translation
- Radiotherapy and Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC): Emerging Synergies and Unresolved Questions
- Kirsten rat sarcoma viral oncogene (KRAS)-targeted therapy across cancer types: Context, resistance, and future directions
- Bridging the Diagnostic Gap in TP53-Mutated Myeloid Neoplasms: From Classification Discrepancies to a Practical cnLOH-Inclusive Diagnostic Framework
- Locoregional-systemic combination therapy reshapes the treatment landscape of intermediate and advanced hepatocellular carcinoma (HCC)
- Cancer-associated critical illness: A paradigm for sharp-phenotype critical illness
- Targeting minimal residual disease (MRD) in colorectal cancer: Therapeutic strategies, clinical trials, and the path toward molecular cure